US Patent

US10961240 — Formulations of a compound modulating kinases

Method of Use · Assigned to Daiichi Sankyo Co Ltd · Expires 2038-07-24 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions of a compound, Pexidartinib hydrochloride, and methods of making and using these compositions.

USPTO Abstract

Provided are compositions comprising Compound I having the following structure: or a pharmaceutically acceptable salt thereof, and a solubilizing agent; methods of making the same; and methods of using the same.

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2606`	—	pexidartinib-hydrochloride
`U-2606`	—	pexidartinib-hydrochloride

Patent Metadata

Patent number: US10961240
Jurisdiction: US
Classification: Method of Use
Expires: 2038-07-24
Drug substance claim: No
Drug product claim: No
Assignee: Daiichi Sankyo Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.